Category: Finance
Closing Bell: Markets up almost 0.1pc on Friday as the cows take control
ASX200 rises by a broken fingernail and just looks flat IT gains offset by Energy losses as uranium stocks get hit hard Really peculiar [more…]
Fatfish subsidiary gets coveted full digital lending license in Malaysia
Fatfish subsidiary SF Direct Sdn Bhd obtains full digital lending licence in Malaysia The tech venture firm is positioning itself to capitalise on opportunities within [more…]
ASX Small Caps and IPO Weekly Wrap: ASX 200 oozes to a fraught +0.75pc weekly ‘win’
Solid early losses this week lead to a very pedestrian finish. ASX 200 benchmark wraps the week +0.75pc better off. Volatile Tech sector ranks [more…]
Monsters of Rock: The Lord taketh away from uranium baggies as Cameco growth plans smash ASX stocks
The lord gives with one hand and takes with the next, a karmic lesson on the circular nature of fortune and misfortune that uranium bag [more…]
ASX Large Caps: Liontown, Boral jump, Cochlear hits record high, but uranium stocks tumble
ASX gains modestly, led by healthcare and tech stocks Bitcoin gains past US$46k Boral surges after huge half year results The ASX 200 gained [more…]
ASX Small Caps Lunch Wrap: Which nation learned (again) that pigeons aren’t into espionage this week?
Local markets are struggling to stay afloat this morning, with the ASX 200 benchmark wavering either side of break-even since the bell rang, following modest [more…]
WTF with DY6: Why rare earths have held strong in the New Year
What’s spurring dysprosium and terbium prices? Who will be the main players in the rare earths market in 2024? And are we seeing a supply [more…]
Resources Top 4: Rare earths hits, graphite deals move the needle as market shakes for battery metals
Venture Minerals shoots to Jupiter on what it says is the highest grade clay rare earths intersection recorded in Australia Synthetic and natural graphite plays [more…]
ASX Health Stocks: Paradigm takes another step forward as Phase 2 trial meets primary endpoint
Paradigm Biopharma’s Phase 2 meets primary endpoint TrivarX collaborates with US university to advance sleep research Paradigm’s successful Phase 2 trial Paradigm Biopharma (ASX:PAR) [more…]
Explorers Podcast: Litchfield Minerals tells all on IPO plans for NT uranium, copper and more
Stockhead’s ‘Garimpeiro’ columnist Barry FitzGerald is back in the studio for another instalment of The Explorers Podcast. In this episode Barry chats to Matthew Pustahya, [more…]
